MedPath

Atropine

Generic Name
Atropine
Brand Names
Atnaa, Atropen, Busulfex, Donnatal, Duodote, Enlon-plus, Isopto Atropine, Lomotil, Minims Atropine Sulphate, Motofen, Phenohytro
Drug Type
Small Molecule
Chemical Formula
C17H23NO3
CAS Number
51-55-8
Unique Ingredient Identifier
7C0697DR9I
Background

Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active. Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products. Atropine is a competitive, reversible antagonist of muscarinic receptors that blocks the effects of acetylcholine and other choline esters. It has a variety of therapeutic applications, including pupil dilation and the treatment of anticholinergic poisoning and symptomatic bradycardia in the absence of reversible causes. Atropine is a relatively inexpensive drug and is included in the World Health Organization List of Essential Medicines.

Indication

The intravenous, intramuscular, subcutaneous, intraosseous and endotracheal use of atropine is indicated for the temporary blockade of severe or life-threatening muscarinic effects. The intramuscular use of atropine in the form of a pen injector is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients. The ophthalmic use of atropine is indicated for mydriasis, cycloplegia, and penalization of the healthy eye in the treatment of amblyopia.

In combination with difenoxin or diphenoxylate (tablets for oral use), atropine is indicated as adjunctive therapy in the management of acute nonspecific diarrhea.

Associated Conditions
Amblyopia, Atrioventricular Heart-block, Bradycardia, Bronchospasm, Crying, Detrusor Hyperreflexia, Excessive bronchial secretion, Hypertonic uterine contraction, Hypertonicity of the small intestine, Ocular Inflammation, Parkinsonism, Peptic Ulcer, Poisoning by parasympathomimetics (cholinergics), Poisoning caused by mushrooms, Poisoning caused by organophosphate anticholinesterase nerve agents, Poisoning caused by organophosphorus pesticides, Pylorospasm, Rhinorrhoea, Sinus Bradycardia, Spasms, Toxic effect of organophosphate and carbamate, Hypermobility of the colon, Laughing, Life-threatening muscarinic side effects, Muscarinic side effects, Severe muscarinic side effects

Daily Low-level Red Light and 0.01% Low-dose Atropine for Myopia Prevention

Not Applicable
Completed
Conditions
Myopia
Interventions
Device: low-level red-light
First Posted Date
2024-12-10
Last Posted Date
2024-12-10
Lead Sponsor
Beijing Tongren Hospital
Target Recruit Count
138
Registration Number
NCT06727019
Locations
🇨🇳

Beijing Tongren Hospital, Beijing, China

The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

Phase 3
Recruiting
Conditions
Myopia
Myopia Progression
Interventions
First Posted Date
2024-11-27
Last Posted Date
2024-12-24
Lead Sponsor
Oupushifang Pharmaceutical Technology Co., Ltd.
Target Recruit Count
606
Registration Number
NCT06708156
Locations
🇨🇳

Hefei Maternal and Child Health Hospital, Hefei, Anhui, China

🇨🇳

The Second Hospital of Anhui Medical University, Hefei, Anhui, China

🇨🇳

Xuancheng People's Hospital, Xuancheng, Anhui, China

and more 22 locations

Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children

Phase 3
Completed
Conditions
Myopia
Interventions
First Posted Date
2024-11-20
Last Posted Date
2024-11-20
Lead Sponsor
Ocumension Therapeutics (Suzhou) Co., Ltd
Target Recruit Count
148
Registration Number
NCT06697522
Locations
🇨🇳

Beijing Children's Hospital, Capital Medical University, Beijing, China

Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control

Not Applicable
Recruiting
Conditions
Myopia
Interventions
Device: Ortho-k lenses
First Posted Date
2024-10-31
Last Posted Date
2025-02-26
Lead Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Target Recruit Count
194
Registration Number
NCT06667037
Locations
🇨🇳

Zhongshan Ophthalmic Center Sun Yat-Sen University, Guangzhou, Guangdong, China

A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

Phase 2
Recruiting
Conditions
Myopia, Progressive
Interventions
First Posted Date
2024-08-30
Last Posted Date
2025-04-25
Lead Sponsor
Sunhawk Vision Biotech, Inc.
Target Recruit Count
144
Registration Number
NCT06579287
Locations
🇨🇳

Chang Cung Memorial Hospital-Tucheng, New Taipei City, Taiwan

🇨🇳

MacKay Memorial Hospital-Tamsui, New Taipei City, Taiwan

🇨🇳

Chung Shan Medical University Hospital, Taichung, Taiwan

and more 4 locations

Changes in Eye Shape With Myopia Management Interventions

Phase 4
Recruiting
Conditions
Myopia
Interventions
Device: MiSight 1-day disposable contact lenses
First Posted Date
2024-06-10
Last Posted Date
2024-10-31
Lead Sponsor
Ohio State University
Target Recruit Count
75
Registration Number
NCT06450132
Locations
🇺🇸

The Ohio State University, Columbus, Ohio, United States

Atropine and Spectacle Combination Treatment (ASPECT): 12-month Results of a Randomized Clinical Trial for Myopia Control

Phase 4
Active, not recruiting
Conditions
Myopia
Interventions
Device: DIMS Lenses
Device: Monofocal lenses
First Posted Date
2024-05-29
Last Posted Date
2024-10-30
Lead Sponsor
Hospital San Carlos, Madrid
Target Recruit Count
111
Registration Number
NCT06431841
Locations
🇪🇸

Noemi Guemes, Madrid, Spain

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

First Posted Date
2024-04-15
Last Posted Date
2025-04-04
Lead Sponsor
Biomedical Advanced Research and Development Authority
Target Recruit Count
46
Registration Number
NCT06366087
Locations
🇺🇸

Johnson County Clin-Trials (JCCT), Lenexa, Kansas, United States

Combination Effect of Optical Defocus and Low Dose Atropine in Myopia Control

Not Applicable
Active, not recruiting
Conditions
Myopia
Interventions
Device: single vision spectacle lenses
Device: Defocus Incorporated Multiple Segments lenses
First Posted Date
2024-04-11
Last Posted Date
2025-01-20
Lead Sponsor
The Hong Kong Polytechnic University
Target Recruit Count
112
Registration Number
NCT06358755
Locations
🇭🇰

Centre for Myopia Research, The Hong Kong Polytechnic University and Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong

Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose Before Tracheal Intubation.

Phase 2
Recruiting
Conditions
Dexmedetomidine
Intubation Complication
Interventions
First Posted Date
2024-03-25
Last Posted Date
2024-03-25
Lead Sponsor
Kasr El Aini Hospital
Target Recruit Count
70
Registration Number
NCT06327399
Locations
🇪🇬

Cairo University Hospitals, Giza, Egypt

© Copyright 2025. All Rights Reserved by MedPath